Sally Pipes(@sallypipes):Generics and biosimilars already fill nearly 90% of U.S. prescriptions. If lawmakers want to lower drug costs, they should start with PBMs and other middlemen whose incentives often steer patients away from cheaper alternatives.

2026.10.08 15:16

Generics and biosimilars already fill nearly 90% of U.S. prescriptions. If lawmakers want to lower drug costs, they should start with PBMs and other middlemen whose incentives often steer patients away from cheaper alternatives.

CSRxP@RxPricing

2026.09.28 20:45

Despite the savings greater biosimilar competition can deliver, Big Pharma continues to game the system to block more affordable alternatives from reaching patients. Lawmakers should build on recent bipartisan work to advance bipartisan, market-based solutions. More from @Axios:

커뮤니티로 전달